drugset / Trial / NCT07282886

VENTURI (VENTilation Using Respiratory Imaging)

NCT07282886 ↗

Phase 2 Recruiting 20 enrolled University of Alabama at Birmingham
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of the study is to enroll participants with uncontrolled asthma to evaluate the large and small airways and drug delivery utilizing two study drugs: * Beclometasone dipropionate/Formoterol fumarate dihydrate/Glycopyrronium bromide (BDP/FF/G) or Trimbow * Fluticasone furoate/Umeclidinium/Vilanterol (FluF/UMEC/VI ) or Trelegy Ellipta

Timeline

Start
2026-03-15
Primary completion
2028-12-31
Completion
2030-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate Unknown 6 ug Inhaled
Subject Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate Unknown 12.5 ug Inhaled
Subject Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate Unknown 100 ug Inhaled
Comparator Fluticasone Furoate/Umeclidinium/Vilanterol Unknown 25 ug Inhaled
Comparator Fluticasone Furoate/Umeclidinium/Vilanterol Unknown 62.5 ug Inhaled
Comparator Fluticasone Furoate/Umeclidinium/Vilanterol Unknown 100 ug Inhaled

Indications